Invanz Add-vantage
Invanz Add-vantage Uses, Dosage, Side Effects, Food Interaction and all others data.
Invanz Add-vantage is a synthetic carbapenem β-lactam antibiotic which inhibits bacterial cell wall synthesis binding to 1 or more penicillin-binding proteins (PBPs). It is active against gm+ve and gm-ve aerobic and anaerobic bacteria and stable against hydrolysis by dehydropeptidase 1 (DHP 1).
Invanz Add-vantage has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.
Trade Name | Invanz Add-vantage |
Availability | Prescription only |
Generic | Ertapenem |
Ertapenem Other Names | Ertapenem |
Related Drugs | amoxicillin, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin, Augmentin |
Weight | 1g |
Type | Injectable powder for injection |
Formula | C22H25N3O7S |
Weight | Average: 475.515 Monoisotopic: 475.141320859 |
Protein binding | Ertapenem is highly bound to human plasma proteins, primarily albumin, in a concentration-dependent manner. The protein binding of ertapenem decreases as plasma concentrations increase. At a plasma concentration of <100 µg/mL, approximately 95% of ertapenem is protein bound. Protein binding of ertapenem decreases to approximately 85% at an approximate plasma concentration of 300 µg/mL. |
Groups | Approved, Investigational |
Therapeutic Class | Other beta-lactam Antibiotics |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Invanz Add-vantage and other antibacterial drugs, Invanz Add-vantage should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. W hen culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Complicated Intra-Abdominal Infections: Invanz Add-vantage is used for the treatment of complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis.
Complicated Skin And Skin Structure Infections, Including Diabetic Foot Infections: Without Osteomyelitis Invanz Add-vantage is used for the treatment of complicated skin and skin structure infections, including diabetic foot infections without osteomyelitisdue to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia. Invanz Add-vantage has not been studied in diabetic foot infections with concomitant osteomyelitis
Community Acquired Pneumonia: Invanz Add-vantage is used for the treatment of community acquired pneumonia due to Streptococcus pneumoniae (penicillin susceptible isolates only) including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis.
Complicated Urinary Tract Infections Including Pyelonephritis: Invanz Add-vantage is used for the treatment of complicated urinary tract infections including pyelonephritis due to Escherichia coli, including cases with concurrent bacteremia, or Klebsiella pneumoniae.
Acute Pelvic Infections Including Postpartum Endomyometritis, Septic Abortion And Post Surgical Gynecologic Infections: Invanz Add-vantage is used for the treatment of acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecological infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia.
Prophylaxis Of Surgical Site Infection Following Elective Colorectal Surgery: Invanz Add-vantage is used for the prevention of surgical site infection following elective colorectal surgery.
Invanz Add-vantage is also used to associated treatment for these conditions: Gynaecological infection, Moderate, severe Community Acquired Pneumonia (CAP), Moderate, severe Complicated Intra-Abdominal Infections, Moderate, severe Complicated Skin and Soft Tissue Infection, Moderate, severe Complicated Urinary Tract Infection, Moderate, severe Diabetic Foot Infection, Moderate, severe Postpartum Endomyometritis, Moderate, severe Septic Abortion
How Invanz Add-vantage works
The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Invanz Add-vantage is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Invanz Add-vantage is hydrolyzed by metallo-beta-lactamases.
Dosage
Invanz Add-vantage dosage
Prophylaxis of surgical infections:
- Adult:1 g as a single dose, to be given 1 hr before the surgery.
Community-acquired pneumonia, Intra-abdominal infections, Skin and skin structure infections, Urinary tract infections:
- Adult:1 g once daily IM (for up to 7 days) or IV infusion over 30 min (for up to 14 days)
- Child:3 mth to 13 yr15 mg/kg bid. Max: 1 g/day.
IV: Dilute powd for inj in 10 mL of sterile water for inj, NaCl 0.9% inj or bacteriostatic water for inj then reconstituted soln should be further diluted with 50 mL NaCl 0.9%. IM: Reconstitute with 3.2 mL of lidocaine 1% inj (witho epinephrine).
Side Effects
Drug rash with eosinophilia and systemic symptoms (DRESS), pruritus, diarrhoea, nausea, vomiting, infused vein complication, phlebitis or thrombophlebitis, headache, muscular weakness, gait disturbance, abnormal coordination, vaginitis; elevations in ALT, AST, alkaline phosphatase and platelet count. Dry mouth, taste disturbances, dyspepsia, abdominal pain, anorexia, constipation, melaena, bradycardia, hypotension, chest pain, oedema, pharyngeal discomfort, dyspnoea, dizziness, sleep disturbances, confusion, asthenia, seizures, raised glucose, petechiae.
Precaution
Patient with known or suspected CNS disorders (e.g. brain lesions, history of seizures). Renal impairment. Pregnancy and lactation.
Interaction
May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations with probenecid.
Food Interaction
No interactions found.Invanz Add-vantage Hypertension interaction
[Moderate] Parenteral ertapenem contains approximately 137 mg (6.0 mEq) of sodium per each gram of ertapenem activity.
The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
Invanz Add-vantage Drug Interaction
Unknown: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprim, diphenhydramine, diphenhydramine, lvp solution, lvp solution, polyethylene glycol 3350, polyethylene glycol 3350, sodium chloride, sodium chloride, acetaminophen, acetaminophen, acetaminophen, acetaminophen, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol, ondansetron, ondansetron
Invanz Add-vantage Disease Interaction
Major: colitis, renal dysfunctionModerate: CNS disorders, hemodialysis, sodium
Volume of Distribution
- 0.12 liter/kg [adults]
- 0.2 liter/kg [pediatric, 3 months to 12 years]
- 0.16 liter/kg [pediatric patients 13 to 17 years]
Elimination Route
Invanz Add-vantage is almost completely absorbed following intramuscular administration. The bioavailability of a 1 g intramuscular dose approximated 92% in 26 healthy subjects [77% male; median (range) age, 29 (22–41) years]. Plasma concentrations of total ertapenem were similar whether given intramuscularly or intravenously.
Half Life
The mean plasma half-life is approximately 4 hours.
Clearance
- 1.8 L/h
Elimination Route
Of the 80% recovered in urine, approximately 38% is excreted as unchanged drug and approximately 37% as the ring-opened metabolite.
Pregnancy & Breastfeeding use
Pregnancy Category B. Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Contraindication
Hypersensitivity to ertapenem, other carbapenems; history of anaphylactic reaction to β-lactams (e.g. penicillins, cephalosporins). Known hypersensitivity to local anaesth of the amide type due to use of lidocaine as diluent in IM use.
Special Warning
Patient undergoing haemodialysis: 500 mg/day; if daily dose given w/in 6 hr prior to haemodialysis, supplemental dose of 150 mg should be administered following the dialysis period.CrCl ≤30 and ESRD: 500 mg/day.
Innovators Monograph
You find simplified version here Invanz Add-vantage
Invanz Add-vantage contains Ertapenem see full prescribing information from innovator Invanz Add-vantage Monograph, Invanz Add-vantage MSDS, Invanz Add-vantage FDA label